03/07/2024
The first of 2024, we've completed episode #3 of the Patient Perspectives series! 🍌❤️ In this installment, we're diving deep into a promising new therapy - Amivantamab - with Pat Gilmore of County Galway, Ireland. It is quite a treat on many fronts, but Pat, an EGFR exon20ins NSCLC fighter just like our Jackie, is one of the first patients to be treated with this drug in the EU.
From discovering this therapy while listening to an evening radio show through to his daughter's swift action to gain audience with a physician on the other side of the country, Pat's experience with Amivantamab has been remarkable. Perhaps most remarkable are his results. Via his 24 months treated with Amivantamab, Pat has achieved a "No Evidence of Disease" (NED) state. This is the goal of any patient handed an advanced-stage cancer diagnosis. As therapies evolve, we firmly believe NED will become more attainable.
While Amivantamab has delivered Pat & his family amazing results thus far, it is not without difficulty or grit. Pat shares his side effects & some helpful methods to manage them. As we've mentioned before, content like this is remarkably absent for patients, care partners & physicians in the cancer community. We're pleased to be able to deliver great information from patient leaders like Pat. As always, big thanks to the ICAN, International Cancer Advocacy Network & Exon 20 Group: EGFR exon 20 & HER2 exon 20 insertions for co-producing this series with us here at the JBF.
Watch Patient Perspectives s01.e03 with Pat Gilmore here on Youtube - https://www.youtube.com/watch?v=Tkh_WsxWL68
